WZ4002 is a potent and selective inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), particularly those containing the T790M resistance mutation. It is primarily used in research settings to study mechanisms of resistance in non-small cell lung cancer (NSCLC). By targeting EGFR with high specificity, WZ4002 helps block downstream signaling pathways that drive tumor cell proliferation and survival. Its application is crucial in developing next-generation therapies for patients who have developed resistance to first-line EGFR inhibitors like gefitinib or erlotinib. Due to its ability to penetrate the central nervous system, it also shows potential in treating brain metastases associated with NSCLC. WZ4002 serves as a valuable tool compound in preclinical studies aimed at understanding kinase inhibitor resistance and optimizing treatment strategies.